Disclosed is a T cell polarizing composition comprising a plurality of metabolites selected from metabolites enriched in non-dysbiotic feces, preferably including one or more of acetate, lactate, indole 3 lactate, 3-(4-hydroxyphenyl)lactate, or phenyllactate, bile acids (cholate, chenodeoxycholate, cholate sulfate), or IFNbeta. Further disclosed is a method of producing the T cell polarizing composition comprising mixing interferon beta (IFNbeta), acetate, lactate, and/or ILA.
The inventions described herein relate generally to compositions comprising bioactive proteins including, but not limited to, enzymes and antimicrobial proteins. Such bioactive protein compositions may be present alone or in a mammalian milk or soy-based nutritional product to increase colonization of desired commensal organisms, reduce potential pathogens, restore microbiome function, and/or otherwise improve health in a mammal consuming same.
The invention described herein relates generally to methods and compositions for administration to modulate the microbiome for the express purpose of increasing host interferon beta (ΙΡΝβ) in mammals of target populations that are at risk for or are being treated for certain inflammatory conditions including infections, viral infection, autoimmune conditions, and recovery from sequalae associated with acute inflammatory insults. In particular, the invention provides a method of elevating the level of ΙΡΝβ in the gut of a mammal by providing the mammal with a live bacterium and a prebiotic that the live bacterium is known to consume. Further, the invention described herein may relate to the administration of compositions found to increase the endogenous production of ΙΡΝβ in the target mammal.
A61K 31/715 - Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkagesDerivatives thereof, e.g. ethers, esters
A61K 31/702 - Oligosaccharides, i.e. having three to five saccharide radicals attached to each other by glycosidic linkages
A61P 37/06 - Immunosuppressants, e.g. drugs for graft rejection
This disclosure describes compositions of one or more components including milk fat globule membranes (MFGM) complexes, milk fat globules (MFG), commensal organisms, SlgA, recombinant SlgA (rSlgA), triglycerides or oils, and mammalian milk oligosaccharides (MMO) and the use of such compositions. The reconstituted MFGM component of the disclosed invention may come from an animal source, particularly from a mammalian source, including from the processing of buttermilk.
A23C 9/14 - Milk preparationsMilk powder or milk powder preparations in which the chemical composition of the milk is modified by non-chemical treatment
A23L 33/00 - Modifying nutritive qualities of foodsDietetic productsPreparation or treatment thereof
A23L 33/115 - Fatty acids or derivatives thereofFats or oils
The inventions described herein relate generally to compositions comprising bioactive proteins including, but not limited to, enzymes and antimicrobial proteins. Such bioactive protein compositions may be present alone or in a mammalian milk or soy-based nutritional product to increase colonization of desired commensal organisms, reduce potential pathogens, restore microbiome function, and/or otherwise improve health in a mammal consuming same.
This invention provides a method of determining risk of necrotizing enterocolitis (NEC) in an infant, comprising the steps of: (a) obtaining a fecal sample of the infant's relevant microbiome; (b) sequencing genetic material in the sample to obtain sequence data for the relevant microbiome; (c) analyzing sequence data for the relevant microbiome to identify biomarkers in the infant's microbiome; and (d) categorizing the NEC risk of the infant using the biomarkers identified in the microbiome of the infant.
C12Q 1/68 - Measuring or testing processes involving enzymes, nucleic acids or microorganismsCompositions thereforProcesses of preparing such compositions involving nucleic acids
C12Q 1/6888 - Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for detection or identification of organisms
C12Q 1/689 - Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for detection or identification of organisms for bacteria
01 - Chemical and biological materials for industrial, scientific and agricultural use
Goods & Services
Chemicals for use in industry, science and photography, as well as in agriculture, horticulture and forestry; unprocessed artificial resins, unprocessed plastics; tempering and soldering preparations; substances for tanning animal skins and hides; adhesives for use in industry; putties and other paste fillers; biological preparations for use in industry and science; precursor for biologically active proteins for use in the manufacture of probiotic based nutritional products; precursor for biologically active proteins for use in the manufacture of probiotic based infant products; precursor for biologically active proteins for use in the manufacture of probiotic based pharmaceutical preparations; biologically active proteins for supporting enhanced bacterial growth; biologically active proteins for consuming foods for microorganisms; acids for use in the preparation of animal foodstuffs; active chemical ingredients for use in the manufacture of pharmaceuticals; chemical and organic compositions for use in the manufacture of food and beverages.
9.
NOVEL OLIGOSACCHARIDES FOR USE IN PREBIOTIC APPLICATIONS
Mare's milk plays a major role in the health of neonatal foals and may be used for human or other mammalian health. Oligosaccharides (OS) possess various bioactivities in many mammalian milks, and Mare's milk may be a source of novel oligosaccharides. The invention relates to the identification of novel structures in mare's milk that may be synthesized or otherwise purified for use in a variety of animal and human applications related to the gut microbiome and mammalian health.
A23C 9/12 - Fermented milk preparationsTreatment using microorganisms or enzymes
A23L 29/30 - Foods or foodstuffs containing additivesPreparation or treatment thereof containing carbohydrate syrupsFoods or foodstuffs containing additivesPreparation or treatment thereof containing sugarsFoods or foodstuffs containing additivesPreparation or treatment thereof containing sugar alcohols, e.g. xylitolFoods or foodstuffs containing additivesPreparation or treatment thereof containing starch hydrolysates, e.g. dextrin
A61K 31/702 - Oligosaccharides, i.e. having three to five saccharide radicals attached to each other by glycosidic linkages
Bifidobacterium,B. infantisB. infantis cell wall components and their uses to treat or prevent diseases, support therapies including metabolic and autoimmune diseases.
A61K 31/702 - Oligosaccharides, i.e. having three to five saccharide radicals attached to each other by glycosidic linkages
A61K 8/99 - Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof, of undetermined constitution from microorganisms other than algae or fungi, e.g. protozoa or bacteria
11.
COMPOSTIONS AND METHOD OF USE FOR H5 COMPETENT BIFIDOBACTERIUM LONGUM SUBSP. INFANTIS
Bifidobacterium longum subsp. infantis comprising a functional H5 cluster, including the Bifidobacterium longum subsp. infantis EVC001 deposited under ATCC Accession No. PTA-125180 may be used in compositions for improving gut health in infants and adults.
in vivo in vivo phenotype during fermentation and processing of food products for human or animal consumption. The methods and compositions of this invention require an activator that acts as a metabolic trigger for Mammalian Milk Oligosaccharide (MMO) consumption phenotype without necessarily requiring oligosaccharides (i.e a sugar polymer of 3 or more monosaccharides) within the fermentation medium. Compositions containing a non-oligosaccharide activator (e.g. monomers and dimers, and combinations thereof) may be used in fermentation processes of this invention. Turning on MMO-related genes without the use of oligosaccharides is one method of preparing activated commensal bacteria. Embodiments of this invention relate to a composition and a method for preparing a stable, activated and dormant form of commensal bacteria such as: bifidobacteria, lactobacilli or pediococci; for consumption by animals or humans, who are nursing or otherwise receiving MMOs as part of their diet.
C12N 1/04 - Preserving or maintaining viable microorganisms
A23C 9/20 - Dietetic milk products not covered by groups
A23L 29/30 - Foods or foodstuffs containing additivesPreparation or treatment thereof containing carbohydrate syrupsFoods or foodstuffs containing additivesPreparation or treatment thereof containing sugarsFoods or foodstuffs containing additivesPreparation or treatment thereof containing sugar alcohols, e.g. xylitolFoods or foodstuffs containing additivesPreparation or treatment thereof containing starch hydrolysates, e.g. dextrin
A23L 33/135 - Bacteria or derivatives thereof, e.g. probiotics
A61K 31/702 - Oligosaccharides, i.e. having three to five saccharide radicals attached to each other by glycosidic linkages
A61K 35/744 - Lactic acid bacteria, e.g. enterococci, pediococci, lactococci, streptococci or leuconostocs
The inventions described herein relate generally to the methods for monitoring the health of the mammalian gut by checking for whether dysbiotic parameters exceed a threshold level or not. In particular, this invention is directed to the use of parameters which correlate with the level of bifidobacteria, especially Bifidobacterium longum subsp. infantis in the mammalian colon.
A01N 43/04 - Biocides, pest repellants or attractants, or plant growth regulators containing heterocyclic compounds having rings with one or more oxygen or sulfur atoms as the only ring hetero atom with one hetero atom
A23C 9/123 - Fermented milk preparationsTreatment using microorganisms or enzymes using only microorganisms of the genus lactobacteriaceaeYoghurt
A23C 9/127 - Fermented milk preparationsTreatment using microorganisms or enzymes using microorganisms of the genus lactobacteriaceae and other microorganisms or enzymes, e.g. kefir, koumiss
This invention provides compositions of oligosaccharides, their preparation, and their use to facilitate the growth of certain beneficial gut bacteria over other gut bacteria in a mammal in order to prevent gastrointestinal distress associated with a major change in gut microflora, such as that which occurs when an infant is weaned from its mother's milk to alternative food sources, or during the recovery of the gut microbiome after a course of oral antibiotics, hospitalization, therapy such as chemotherapy or radiation treatments, or conditions where a deficiency in dietary fiber is observed. Novel compositions of oligosaccharides, oligosaccharides and bacteria, foods comprising those compositions, and methods of preparation and use of those compositions are described.
A23L 1/00 - Foods or foodstuffs; Their preparation or treatment (preservation thereof in general A23L 3/00)
A23L 1/09 - containing carbohydrate syrups; containing sugars; containing sugar alcohols, e.g. xylitol; containing starch hydrolysates, e.g. dextrin (A23L 1/76, A23L 1/236 take precedence);;
A23L 29/30 - Foods or foodstuffs containing additivesPreparation or treatment thereof containing carbohydrate syrupsFoods or foodstuffs containing additivesPreparation or treatment thereof containing sugarsFoods or foodstuffs containing additivesPreparation or treatment thereof containing sugar alcohols, e.g. xylitolFoods or foodstuffs containing additivesPreparation or treatment thereof containing starch hydrolysates, e.g. dextrin
The inventions described herein relate generally to the use of compositions to increase output of particular metabolites in the gut of a nursing infant mammal including humans. These compositions generally comprise one or more bacterial strains selected for their growth on mammalian milk oligosaccharides, a source of mammalian milk oligosaccharides, and, optionally, nutritive components required for the growth of that infant mammal.
05 - Pharmaceutical, veterinary and sanitary products
Goods & Services
In vitro medical diagnostic test kits for clinical, professional, medical or consumer use consisting primarily of reagents and assays together with test equipment in the nature of a marker of bifidobacterium abundance; medical diagnostic test media in the form of liquid and strips for measuring infant health and wellness and nutrient utilization; diagnostic kits comprised of medical diagnostic reagents for screening infant gut microbiome; medical diagnostic reagents and assays for testing infant stool.
05 - Pharmaceutical, veterinary and sanitary products
Goods & Services
(1) In vitro medical diagnostic test kits for clinical, professional, medical and consumer use consisting primarily of reagents and assays together with test equipment in the nature of a marker of Bifidobacterium abundance; medical diagnostic test media in the form of liquid and strips for measuring infant general health and well-being and nutrient utilization; Diagnostic kits comprised of medical diagnostic reagents for screening infant gut microbiome; Medical diagnostic reagents and assays for testing infant stool
05 - Pharmaceutical, veterinary and sanitary products
Goods & Services
Sanitary preparations for medical purposes; dietetic food and substances adapted for medical or veterinary use, food for babies; dietary supplements for humans and animals; plasters, materials for dressings; material for stopping teeth, dental wax; disinfectants; preparations for destroying vermin; fungicides, herbicides; dietary and nutritional supplements for developing infant gut microbiome; non-pharmaceutical preparations of probiotics and prebiotics for pregnant women, mothers and their infants; probiotic and prebiotic supplements for pregnant women, mothers, and their infants; vitamin and mineral supplements; anti-oxidant food supplements; dietary and nutritional supplements; antioxidants; delivery agents in the form of dissolvable films that facilitate the delivery of nutritional supplements; delivery agents in the form of coatings for tablets that facilitate the delivery of nutritional supplements; dietary supplemental drinks; dietary food supplements; food supplements; infant formula; food for infants; health food supplements for persons with special dietary requirements; health food supplements made principally of vitamins; health food supplements made principally of minerals; medicated food supplements; probiotic supplements; protein dietary supplements; dietary supplements for infants; dietetic preparations for children; probiotic and prebiotic formulations for medical use; amino acids for medical purposes.
19.
METHOD FOR FACILITATING MATURATION OF THE MAMMALIAN IMMUNE SYSTEM
The inventions described herein relate generally to the use of compositions to increase output of acetate and lactate while reducing pH and the levels of pathogenic bacteria and inflammation in the gut of a nursing infant mammal including humans. These compositions generally comprise one or more bacterial strains selected for their growth on mammalian milk oligosaccharides, a source of mammalian milk oligosaccharides, and, optionally, nutritive components required for the growth of that infant mammal.
05 - Pharmaceutical, veterinary and sanitary products
Goods & Services
(1) Dietary and nutritional supplements for developing infant gut microbiome; non-pharmaceutical preparations of probiotics and prebiotics for pregnant women, mothers and their infants
21.
A TRANSIENT COMMENSAL MICROORGANISM FOR IMPROVING GUT HEALTH
The inventions described herein relate generally to administering compounds to promote mucosal healing in mammals in need thereof including, but not limited to humans. The compounds may include bifidobacteria and mammalian milk oligosaccharides.
The inventions described herein relate generally to digestive healthcare, and more particularly, to the feeding of mammals, particularly human infants, who are making a transition from a inicrobiome with lower diversity to a microbiome with higher diversity. These inventions relate to certain foods comprising a fermentable nutritional component and a probiotic component, where the probiotic component is selected, based on genetic and/or metabolic criteria, to specifically metabolize any Free Sugar Monomers (FSMs) and Free Amino Acids (FAAs) or peptides that accumulate as a result of the fermentable nutritional component in the lower intestine, where they otherwise might be left in the environment to be fermented and metabolized by less adapted/opportunistic bacteria, creating blooms of deleterious intestinal bacteria and shifting the microbiome to a potentially dysbiotic state. The present inventions provide combinations of foods and probiotic bacteria that can protect the mammalian gut from blooms of pathogenic bacteria.
05 - Pharmaceutical, veterinary and sanitary products
Goods & Services
(1) Dietary and nutritional supplements for developing infant gut microbiome; probiotic and prebiotic supplements for pregnant women, mothers, and their infants
05 - Pharmaceutical, veterinary and sanitary products
Goods & Services
Pharmaceuticals, medical and veterinary preparations; sanitary preparations for medical purposes; dietetic food and substances adapted for medical or veterinary use, food for babies; dietary supplements for humans and animals; plasters, materials for dressings; material for stopping teeth, dental wax; disinfectants; preparations for destroying vermin; fungicides, herbicides; human infant supplements, namely, dietary, nutritional, and probiotic supplements; dietetic beverages adapted for medical purposes; dietetic foods adapted for medical purposes; digestives for pharmaceutical purposes; enzyme dietary supplements; linseed dietary supplements; medicinal drinks; medicinal healthcare preparations; milk ferments for pharmaceutical purposes; mineral food supplements; nutritional supplements; nutritive substances for microorganisms; pastilles for pharmaceutical purposes; protein dietary supplements; vitamin supplements; probiotic supplements; food supplements; preparations of microorganisms for medical use; food supplements for medical purposes; health food supplements made principally of vitamins; health food supplements made principally of minerals; homeopathic supplements; herbal dietary supplements for persons special dietary requirements; infant formula; beverages for infants; food for infants; dietary supplements and preparations for infants and children; powdered milk foods for infants; dietetic preparations for children; baby foods; medicated baby powders; medicated baby oils; baby diapers.
42 - Scientific, technological and industrial services, research and design
Goods & Services
Scientific and technological services and research and design relating thereto; industrial analysis and research services; design and development of computer hardware and software; development of microbiome preparations for food, food supplements, and medicines; research and development of new products for others; research and development in the field of microorganisms and cells; research on food; research relating to medicine; scientific laboratory services; technical consultancy in relation to research services relating to foods and dietary supplements; food sanitation consultancy; inspection and testing of foodstuffs; quality control relating to the hygiene of foodstuffs; computerised food analysis services; professional advisory services relating to food technology; research and development of vaccines and medicines; bacteriological research; biological research; chemical analysis and research; clinical trials; development of pharmaceutical preparations and medicines; medical laboratories; medical research; microbiological testing; medical and scientific research in the field of pharmaceuticals and clinical trials; providing scientific information in the field of medical disorders and their treatment; information, consultancy and advisory services for all the aforementioned services.
42 - Scientific, technological and industrial services, research and design
Goods & Services
(1) Development of microbiome preparations for food, food supplements, and medicines, namely, dietary, nutritional, and probiotic supplements in the form of tablets, capsules, powders and drops for maintaining gastrointestinal health and well-being
Devices and methods for delivering non-pathogenic, intestinally beneficial bacteria to a patient having a feeding tube. Examples of non-pathogenic, intestinally beneficial bacteria that could be used include Bifidobacterium species and Lactobacillus species. In one embodiment, the bacteria is contained in a bacteria infusion device that comprises: (a) an internal chamber; (b) an outlet in communication with the internal chamber; and (c) the non-pathogenic, intestinally beneficial bacteria contained in the internal chamber. Another embodiment is a feeding tube comprising a flexible tubing and coating on the outer surface of the flexible tubing. The coating comprises an antimicrobial agent. Also disclosed are methods of administering a non-pathogenic, intestinally beneficial bacteria to a patient.
A23G 1/50 - Cocoa products, e.g. chocolateSubstitutes therefor characterised by shape, structure or physical form, e.g. products with an inedible support
A23G 1/56 - Liquid productsSolid products in the form of powders, flakes or granules for making liquid products, e.g. for making chocolate milk
30.
COMPOSITIONS THAT METABOLIZE OR SEQUESTER FREE SUGAR MONOMERS AND USES THEREOF
Compositions comprising at least two non-pathogenic microbes are described herein. The non-pathogenic microbes may be from a first species capable of internalizing and/or metabolizing dietary glycans and/or from a second species capable of consuming and metabolizing free sugar monomers. Methods of making and use in treating and/or preventing the overgrowth of pathogenic bacteria in mammals are also described herein.
Some embodiments of the invention include a kit and a device for detecting activated bifidobacteria. Methods of making and using the kit and/or device are also described herein.
Some embodiments of the invention include a composition and method for treating dysbiosis in infants. The composition may include a mixture of activated bifidobacteria and a complex oligosaccharide wherein the complex oligosaccharide may be derived from a human or non-human source.
